ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

VYGR Voyager Therapeutics Inc

8,81
0,28 (3,28%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Voyager Therapeutics Inc VYGR NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,28 3,28% 8,81 06:00:09
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
8,76 8,61 8,92 8,81 8,53
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
22.4.202422:30GLOBEVoyager Therapeutics to Present Broad Set of Translational..
16.4.202413:00GLOBEVoyager Therapeutics Announces Selection of Development..
26.3.202421:01GLOBEVoyager Therapeutics Announces Inducement Grants Under..
13.3.202412:00GLOBEVoyager Therapeutics Announces Appointment of Toby Ferguson..
28.2.202422:01GLOBEVoyager Therapeutics Reports Fourth Quarter and Full Year..
28.2.202422:00EDGAR2Form 8-K - Current report
26.2.202413:00GLOBEVoyager Therapeutics Announces Selection of Gene Therapy..
22.2.202422:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202421:16EDGAR2Form 144 - Report of proposed sale of securities
21.2.202421:13EDGAR2Form 144 - Report of proposed sale of securities
21.2.202413:00GLOBEVoyager Therapeutics Announces Fourth Quarter 2023..
20.2.202421:11EDGAR2Form 144 - Report of proposed sale of securities
20.2.202413:00GLOBEVoyager Therapeutics Reports Robust Preclinical Activity in..
16.2.202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.2.202413:00GLOBEVoyager Therapeutics to Present at the Oppenheimer Annual..
19.1.202422:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202422:20EDGAR2Form D - Notice of Exempt Offering of Securities
17.1.202421:33EDGAR2Form 144 - Report of proposed sale of securities
17.1.202421:21EDGAR2Form 144 - Report of proposed sale of securities
08.1.202422:49EDGAR2Form 8-K - Current report
08.1.202422:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05.1.202404:45GLOBEVoyager Therapeutics Announces Pricing of Public Offering
04.1.202423:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04.1.202422:14GLOBEVoyager Therapeutics Announces Proposed Public Offering
03.1.202413:00GLOBEVoyager Therapeutics to Present at the 42nd Annual J.P...
02.1.202413:46DJNVoyager Therapeutics Shares Leap Premarket on Novartis..
02.1.202413:05EDGAR2Form 8-K - Current report
02.1.202413:00GLOBEVoyager Therapeutics Enters Capsid License Agreement and..
06.12.202313:04EDGAR2Form 8-K - Current report
06.12.202313:00GLOBEVoyager Therapeutics Announces Selection of Development..
06.11.202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06.11.202322:01GLOBEVoyager Therapeutics Reports Third Quarter 2023 Financial..
06.11.202322:00EDGAR2Form 8-K - Current report
30.10.202312:00GLOBEVoyager Therapeutics Announces Third Quarter 2023 Conference..
02.10.202322:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.9.202313:00GLOBEVoyager Therapeutics to Present at the Chardan Genetic..
18.9.202322:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.9.202319:57EDGAR2Form 144 - Report of proposed sale of securities
07.9.202322:01GLOBEVoyager Therapeutics Announces Inducement Grants Under..
30.8.202313:00GLOBEVoyager Therapeutics to Participate in Upcoming Investor..
16.8.202322:18EDGAR2Form 8-K - Current report
08.8.202322:01GLOBEVoyager Therapeutics Announces Inducement Grants Under..
07.8.202314:00GLOBEVoyager Therapeutics Announces Appointment of Beth Shafer as..
03.8.202313:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03.8.202313:00EDGAR2Form 8-K - Current report
03.8.202313:00GLOBEVoyager Therapeutics Reports Second Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock